Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Lipocine (LPCN) EBIT Margin (2018 - 2025)

Historic EBIT Margin for Lipocine (LPCN) over the last 8 years, with Q3 2025 value amounting to 2933.51%.

  • Lipocine's EBIT Margin changed N/A to 2933.51% in Q3 2025 from the same period last year, while for Sep 2025 it was 145.98%, marking a year-over-year decrease of 753000.0%. This contributed to the annual value of 10.31% for FY2024, which is 6186600.0% up from last year.
  • As of Q3 2025, Lipocine's EBIT Margin stood at 2933.51%.
  • In the past 5 years, Lipocine's EBIT Margin registered a high of 4515.52% during Q1 2021, and its lowest value of 7889.86% during Q1 2023.
  • Its 5-year average for EBIT Margin is 1429.79%, with a median of 386.03% in 2025.
  • In the last 5 years, Lipocine's EBIT Margin soared by 79321600bps in 2024 and then tumbled by -22691300bps in 2025.
  • Lipocine's EBIT Margin (Quarter) stood at 79.47% in 2021, then tumbled by -988bps to 705.51% in 2022, then skyrocketed by 270bps to 1199.58% in 2023, then tumbled by -96bps to 44.27% in 2024, then crashed by -6727bps to 2933.51% in 2025.
  • Its last three reported values are 2933.51% in Q3 2025, 386.03% for Q2 2025, and 2226.82% during Q1 2025.